Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Clarithromycin or Cyclosporine on PK of Mindeudesivir in Healthy Subjects
NCT06005714Phase 1Completed
- Sponsor
- Shanghai Vinnerna Biosciences Co., Ltd.
- Start
- Aug 2023
- Primary completion
- Oct 2023
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, open-label trial of deuremidevir in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Shanghai Vinnerna Biosciences Co., Ltd. Primary endpoints: Area Under the Plasma Concentration-Time Curve from Time Zero to Time t up to 14 days and Maximum Plasma Concentration up to 14 days. Started Aug 2023; status: completed.
02
Drugs
deuremidevir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06005714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06005714.